Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Stock Short Interest Climbs 5,345.3%

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) was the recipient of a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 2,886 shares, an increase of 5,345.3% from the October 15th total of 53 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 1,238 shares, the short-interest ratio is presently 2.3 days.

Orion OYJ Trading Up 0.6%

Shares of Orion OYJ stock opened at $57.25 on Thursday. The firm has a market cap of $16.16 billion, a price-to-earnings ratio of 21.13 and a beta of 0.05. The business has a 50-day moving average price of $49.93 and a 200-day moving average price of $42.47. The company has a quick ratio of 1.48, a current ratio of 2.64 and a debt-to-equity ratio of 0.08. Orion OYJ has a twelve month low of $33.62 and a twelve month high of $58.15.

Orion OYJ (OTCMKTS:ORINY) last posted its earnings results on Wednesday, October 28th. The company reported $0.68 EPS for the quarter. Orion OYJ had a return on equity of 54.09% and a net margin of 30.25%. The company had revenue of $623.96 million for the quarter.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group raised Orion OYJ from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 26th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy”.

Orion OYJ Company Profile

Orion Oyj is a Finnish pharmaceutical company that develops, manufactures and markets medicines for human and veterinary use. Its portfolio includes prescription and over-the-counter medicines, as well as active pharmaceutical ingredients supplied to other pharmaceutical companies. Founded in 1917 and headquartered in Espoo, Finland, Orion has a long history in the pharmaceutical industry. The company focuses on areas including oncology, neurology and respiratory diseases, and develops some products in collaboration with international pharmaceutical partners.